Contineum Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Contineum Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 81% of its market value (net cash). Higher than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-59.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 75% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-23.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 59% of Healthcare companies in United States.
Cash Cushion Ratio
+81%Cash, after subtracting all debt, equals 81% of its market value (net cash).
Higher than 85% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Contineum Therapeutics, Inc. made a loss over the last year. Contineum Therapeutics, Inc. owes $0.04 for every $1 it owns. Contineum Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossContineum Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.30The share price is 1.30 times Contineum Therapeutics, Inc.'s book value per share, lower than 72% of Healthcare companies in United States.
Market cap
$313 MThe total market value of all of Contineum Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$240 MWhat Contineum Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.37Net worth divided by the number of shares. The share price of $8.31 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
-28.0%Contineum Therapeutics, Inc. lost 28.0% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
Owes vs Owns
0.04×Contineum Therapeutics, Inc. owes $0.04 for every $1 it owns (low), lower than 97% of Healthcare companies in United States.
Dividend yield
NoneContineum Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossContineum Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashContineum Therapeutics, Inc. held $255 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Contineum Therapeutics, Inc.: $313 M ÷ $240 M (30 Jun 2026) = 1.3.
What is Contineum Therapeutics, Inc.'s return on equity?
Contineum Therapeutics, Inc. lost 28.0% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
How much does Contineum Therapeutics, Inc. owe compared with what it owns?
Contineum Therapeutics, Inc. owes $0.04 for every $1 it owns (low), lower than 97% of Healthcare companies in United States.
Does Contineum Therapeutics, Inc. pay a dividend?
No. Contineum Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.